Last reviewed · How we verify
AlloStim8 or AlloStim-9
At a glance
| Generic name | AlloStim8 or AlloStim-9 |
|---|---|
| Also known as | Immune activation phase |
| Sponsor | Mirror Biologics, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- In-Situ Therapeutic Cancer Vaccine for Metastatic Cancer Combining AlloStim With Tumor Cryoablation (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AlloStim8 or AlloStim-9 CI brief — competitive landscape report
- AlloStim8 or AlloStim-9 updates RSS · CI watch RSS
- Mirror Biologics, Inc. portfolio CI